Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis

References

• Neuhaus O, Archelos JJ, Hartung HP. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol. Sci.24, 131–138 (2003).
   PubMed Web of Science ®Google Scholar
• Wiendl H, Kieseier BC. Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Exp. Opin. Investig. Drugs12, 689–712 (2003).
   PubMed Web of Science ®Google Scholar
• Soldan SS, Retuerto AI, Sicotte NL, Voskuhl RR. Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J. Immunol.171, 6267–6274 (2003).
   PubMed Web of Science ®Google Scholar
• Dalal M, Kim S, Voskuhl RR. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantigen-specific T lymphocyte response. J. Immunol.159, 3–6 (1997).
   PubMed Web of Science ®Google Scholar
• Bielekova B, Lincoln A, McFarland HF, Martin R. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J. Immunol.164, 1117–1124 (2000).
   PubMedGoogle Scholar
• Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell. Mol. Biol.49, 277–300 (2003).
   PubMed Web of Science ®Google Scholar
• Fernandez O, Fernandez V, De Ramon E. Azathioprine and methotrexate in multiple sclerosis. J. Neurol. Sci.223, 29–34 (2004).
   PubMed Web of Science ®Google Scholar
• The IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing–remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology43, 655–661 (1993).
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β-1a for disease progression in exacerbating-remitting multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol.39, 285–294 (1996).
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet352, 1498–1504 (1998).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a Phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology45, 1268–1276 (1995).
   PubMed Web of Science ®Google Scholar
• Kieseier BC, Hartung HP. Current disease-modifying therapies in multiple sclerosis. Semin. Neurol.23, 133–145 (2003).
   PubMed Web of Science ®Google Scholar
• Hartung HP, Gonsette R, König N et al. A placebo-controlled, double-blind, randomised, multicentre trial of mitoxantrone in progressive multiple sclerosis. Lancet360, 2018–2025 (2002).
   PubMed Web of Science ®Google Scholar
• Neuhaus O, Kieseier BC, Hartung HP. Therapeutic role of mitoxantrone in multiple sclerosis. Pharmacol. Ther.109, 198–209 (2006).
   PubMed Web of Science ®Google Scholar
• Shenkenberg TD, von Hoff D. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann. Intern. Med.105, 67–81 (1986).
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med.354, 899–910 (2006).
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon β-1a for relapsing multiple sclerosis. N. Engl. J. Med.354, 911–923 (2006).
   PubMed Web of Science ®Google Scholar
• Rice GP, Hartung HP, Calabresi PA. Anti-α4 integrin therapy for multiple sclerosis. Mechanisms and rationale. Neurology64, 1336–1342 (2005).
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med.354, 924–933 (2006).
   PubMed Web of Science ®Google Scholar
• Polman CH, Uitdehaag BM. New and emerging treatment options for multiple sclerosis. Lancet Neurol.2, 563–566 (2003).
   PubMed Web of Science ®Google Scholar
• Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol.6, 358–370 (2006).
   PubMed Web of Science ®Google Scholar
• Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol.19, 117–125 (2005).
   PubMed Web of Science ®Google Scholar
• Kurakata S, Kada M, Shimada Y, Komai T, Nomoto K. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro. Immunopharmacology34, 51–61 (1996).
   PubMed Web of Science ®Google Scholar
• Botti RE, Triscari J, Pan HY, Zayat J. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin. Neuropharmacol.14, 256–261 (1991).
   PubMed Web of Science ®Google Scholar
• Saheki A, Terasaki T, Tamai I, Tsuji A. In vivo and in vitro blood–brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharmacol. Res.11, 305–311 (1994).
   Google Scholar
• Rajanikant GK, Zemke D, Kassab M, Majid A. The therapeutic potential of statins in neurological disorders. Curr. Med. Chem.14, 103–112 (2007).
   PubMed Web of Science ®Google Scholar
• Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxa-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug–drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther.112, 71–105 (2006).
   PubMed Web of Science ®Google Scholar
• Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin. Pharmacol. Ther.64, 58–65 (1998).
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Kantola T, Kivistö KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther.63, 332–341 (1998).
   PubMed Web of Science ®Google Scholar
• Massy ZA, Guijarro C. Statins: effects beyond cholesterol lowering. Nephrol. Dial. Transplant.16, 1738–1741 (2001).
   PubMed Web of Science ®Google Scholar
• Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler. Thromb. Vasc. Biol.21, 1712–1719 (2001).
   PubMed Web of Science ®Google Scholar
• Larosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA282, 2340–2346 (1999).
   PubMed Web of Science ®Google Scholar
• Ridker PM. Connecting the role of C-reactive protein and statins in cardiovascular disease. Clin. Cardiol.26, III39–III44 (2003).
   PubMedGoogle Scholar
• Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation109, III39–III43 (2004).
   PubMed Web of Science ®Google Scholar
• Chan KKW, Oza AM, Siu LL. The statins as anticancer agents. Clin. Cancer Res.9, 10–19 (2003).
   PubMed Web of Science ®Google Scholar
• Jakobisiak M, Golab J. Potential antitumor effects of statins. Int. J. Oncol.23, 1055–1069 (2003).
   PubMed Web of Science ®Google Scholar
• Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet356, 1627–1631 (2000).
   PubMed Web of Science ®Google Scholar
• Pahan K. Lipid-lowering drugs. Cell. Mol. Life Sci.63, 1165–1178 (2006).
   PubMed Web of Science ®Google Scholar
• White HD, Simes RJ, Anderson NE et al. Pravastatin therapy and the risk of stroke. N. Engl. J. Med.343, 317–326 (2000).
   PubMed Web of Science ®Google Scholar
• Amarenco P, Bogousslavsky J, Callahan AR et al. High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med.355, 549–559 (2006).
   PubMed Web of Science ®Google Scholar
• Paintlia AS, Paintlia MK, Khan M, Vollmer T, Singh AK, Singh I. HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis. FASEB J.19, 1407–1421 (2005).
   PubMed Web of Science ®Google Scholar
• Lim JH, Lee JC, Choi IY et al. Simvastatin prevents oxygen and glucose deprivation/reoxygenation-induced death of cortical neurons by reducing the production and toxicity of 4-hydroxy-2E-nonenal. J. Neurochem.97, 140–150 (2006).
   PubMed Web of Science ®Google Scholar
• Franke C, Noldner M, Abel-Kader R et al. Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiol. Dis.25, 438–445 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson-Anuna LN, Eckert GP, Franke C, Iqbavboa U, Muller WE, Wood WG. Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J. Neurochem.101(1), 77–86 (2007).
   PubMed Web of Science ®Google Scholar
• Cutts JL, Scallen TJ, Watson J, Bankhurst AD. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J. Cell. Physiol.139, 550–557 (1989).
   PubMed Web of Science ®Google Scholar
• Kobashigawa JA, Katznelson S, Laks H et al. Effects of pravastatin on outcomes after cardiac transplantation. N. Engl. J. Med.333, 621–627 (1995).
   PubMed Web of Science ®Google Scholar
• Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol. Sci.23, 482–486 (2002).
   PubMed Web of Science ®Google Scholar
• Jain KK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat. Rev. Drug Discov.4, 977–987 (2005).
   PubMed Web of Science ®Google Scholar
• McCarey DW, McInnes IB, Madhok R et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet363, 2015–2021 (2004).
   PubMed Web of Science ®Google Scholar
• Neuhaus O, Stüve O, Zamvil SS, Hartung HP. Are statins a treatment option for multiple sclerosis? Lancet Neurol.3, 369–371 (2004).
   PubMed Web of Science ®Google Scholar
• Weber MS, Prod’homme T, Steinman L, Zamvil SS. Drug insight: using statins to treat neuroinflammatory disease. Nat. Clin. Pract. Neurol.1, 106–112 (2005).
   PubMedGoogle Scholar
• Neuhaus O, Stüve O, Archelos JJ, Hartung HP. Putative mechanisms of action of statins in multiple sclerosis – comparison to interferon-β and glatiramer acetate. J. Neurol. Sci.233, 173–177 (2005).
   PubMedGoogle Scholar
• Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J. Clin. Invest.100, 2671–2679 (1997).
   PubMed Web of Science ®Google Scholar
• Singh R, Wang B, Shirvaikar A et al. The IL-1 receptor and Rho directly associate to drive cell activation in inflammation. J. Clin. Invest.103, 1561–1570 (1999).
   PubMedGoogle Scholar
• Tang W, Chang SB, Hemler ME. Links between CD147 function, glycosylation, and caveolin-1. Mol. Biol. Cell15, 4043–4050 (2004).
   PubMed Web of Science ®Google Scholar
• Schenk B, Fernandez F, Waechter CJ. The ins(ide) and out(side) of dolichyl phosphate biosynthesis and recycling in the endoplasmic reticulum. Glycobiology11, 61R–70R (2001).
   PubMed Web of Science ®Google Scholar
• Siddals KW, Marshman E, Westwood M, Gibson JM. Abrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion. J. Biol. Chem.279, 38353–38359 (2004).
   PubMed Web of Science ®Google Scholar
• Carlberg M, Dricu A, Blegen H et al. Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. J. Biol. Chem.271, 17453–17462 (1996).
   PubMed Web of Science ®Google Scholar
• Kuipers HF, Biesta PJ, Groothuis TA, Neefjes JJ, Mommaas AM, van den Elsen PJ. Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. Hum. Immunol.66, 653–665 (2005).
   PubMed Web of Science ®Google Scholar
• Kirsch C, Eckert GP, Mueller WE. Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem. Pharmacol.65, 843–856 (2003).
   PubMed Web of Science ®Google Scholar
• Weitz-Schmidt G, Welzenbach K, Brinkmann V et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med.7, 687–692 (2001).
   PubMed Web of Science ®Google Scholar
• Archelos JJ, Hartung HP. The role of adhesion molecules in multiple sclerosis: biology, pathogenesis and therapeutic implications. Mol. Med. Today3, 310–321 (1997).
   PubMedGoogle Scholar
• Stanislaus R, Pahan K, Singh AK, Singh I. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci. Lett.269, 71–74 (1999).
   PubMed Web of Science ®Google Scholar
• Stanislaus R, Singh AK, Singh I. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J. Neurosci. Res.66, 155–162 (2001).
   PubMed Web of Science ®Google Scholar
• Youssef S, Stüve O, Patarroyo JC et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in CNS autoimmune disease. Nature420, 78–84 (2002).
   PubMed Web of Science ®Google Scholar
• Aktas O, Waiczies S, Smorodchenko A et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med.197, 725–733 (2003).
   PubMed Web of Science ®Google Scholar
• Greenwood J, Walters CE, Pryce G et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J.17, 905–907 (2003).
   PubMed Web of Science ®Google Scholar
• Nath N, Giri S, Prasad R, Singh AK, Singh I. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for multiple sclerosis therapy. J. Immunol.172, 1273–1286 (2004).
   PubMed Web of Science ®Google Scholar
• Sattler MB, Diem R, Merkler D et al. Simvastatin treatment does not protect retinal ganglion cells from degeneration in a rat model of autoimmune optic neuritis. Exp. Neurol.193, 163–171 (2005).
   PubMedGoogle Scholar
• Dunn SE, Youssef S, Goldstein MJ et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J. Exp. Med.203, 401–412 (2006).
   PubMed Web of Science ®Google Scholar
• Stüve O, Youssef S, Weber MS et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J. Clin. Invest.116, 1037–1044 (2006).
   PubMed Web of Science ®Google Scholar
• Neuhaus O, Strasser-Fuchs S, Fazekas F et al. Statins as immunomodulators: comparison with interferon-β1b in MS. Neurology59, 990–997 (2002).
   PubMed Web of Science ®Google Scholar
• Matsumoto M, Einhaus D, Gold ES, Aderem A. Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. J. Immunol.172, 7377–7384 (2004).
   PubMed Web of Science ®Google Scholar
• Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat. Med.6, 1399–1402 (2000).
   PubMed Web of Science ®Google Scholar
• Vollmer T, Key L, Durkalski V et al. Oral simvastatin treatment in relapsing–remitting multiple sclerosis. Lancet363, 1607–1608 (2004).
   PubMed Web of Science ®Google Scholar
• Daumer M, Kessner S, Lederer C, Neiss A. Modelling placebo groups for clinical trials. Mult. Scler.9(Suppl. 1), S22 (2003).
   Google Scholar
• Davidson MH. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs61, 197–206 (2001).
   PubMed Web of Science ®Google Scholar
• Gotto AMJ. Safety and statin therapy: reconsidering the risks and benefits. Arch. Intern. Med.163, 657–659 (2003).
   PubMedGoogle Scholar
• Wortmann RL. Lipid-lowering agents and myopathy. Curr. Opin. Rheumatol.14, 643–647 (2002).
   PubMed Web of Science ®Google Scholar
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA289, 1681–1690 (2003).
   PubMed Web of Science ®Google Scholar
• Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med.346, 539–540 (2002).
   PubMed Web of Science ®Google Scholar
• Graham DJ, Staffa JA, Shatin D et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA292, 2585–2590 (2004).
   PubMed Web of Science ®Google Scholar
• Muldoon MF, Flory JD, Marsland A, Manuck S, Whiteside TL, Rabin B. Effects of lovastatin on the immune system. Am. J. Cardiol.80, 1391–1394 (1997).
   PubMed Web of Science ®Google Scholar
• Nakamichi K, Saiki M, Kitani H et al. Suppressive effect of simvastatin on interferon-β-induced expression of CC chemokine ligand 5 in microglia. Neurosci. Lett.407, 205–210 (2006).
   PubMed Web of Science ®Google Scholar
• Kanter JL, Narayana S, Ho PP et al. Lipid microarrays identify key mediators of autoimmune brain inflammation. Nat. Med.12, 138–143 (2006).
   PubMed Web of Science ®Google Scholar
• Björkbacka H, Kunjathoor VV, Moore KJ et al. Reduced atherosclerosis in MyD88- null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med.10, 416–421 (2004).
   PubMed Web of Science ®Google Scholar
• Ghittoni R, Napolitani G, Benati D et al. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur. J. Immunol.36, 2885–2893 (2006).
   PubMed Web of Science ®Google Scholar
• Sakai M, Kobori S, Matsumura T et al. HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density liproprotein. Atherosclerosis133, 51–59 (1997).
   PubMed Web of Science ®Google Scholar
• Aikawa M, Rabkin E, Sugiyama S et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases, and tissue factor in vivo, and in vitro. Circulation103, 276–283 (2001).
   PubMed Web of Science ®Google Scholar
• Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int. J. Immunopharmacol.18, 669–675 (1996).
   PubMed Web of Science ®Google Scholar
• Honjo M, Tanihara H, Nishijima K et al. Statin inhibits leukocyte–endothelial interaction and prevents neuronal death induced by ischemia-reperfusion injury in the rat retina. Arch. Ophthalmol.120, 1707–1713 (2002).
   PubMedGoogle Scholar
• Diomede L, Albani D, Sottocorno M et al.In vivo anti-inflammatory effects of statins is mediated by nonsterol mevalonate products. Arterioscler. Thromb. Vasc. Biol.21, 1327–1332 (2001).
   PubMed Web of Science ®Google Scholar
• Rudich SM, Mongini PKA, Perez RV, Katznelson S. HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human β-lymphocyte activation. Transplant. Proc.30, 992–995 (1998).
   PubMed Web of Science ®Google Scholar
• Waiczies S, Prozorovski T, Infante-Duarte C et al. Atorvastatin induces T cell anergy via phosphorylation of ERK1. J. Immunol.174, 5630–5635 (2005).
   PubMed Web of Science ®Google Scholar
• Peng X, Jin J, Giri S et al. Immunomodulatory effects of 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, potential therapy for relapsing remitting multiple sclerosis. J. Neuroimmunol.178, 130–139 (2006).
   PubMedGoogle Scholar
• Ifergan I, Wosik K, Cayrol R et al. Statins reduce human blood–brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann. Neurol.60, 45–55 (2006).
   PubMed Web of Science ®Google Scholar
• Zacco A, Togo J, Spence K et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J. Neurosci.23, 11104–11111 (2003).
   PubMed Web of Science ®Google Scholar